Use proven scientific methods and rigorous research to develop and deliver nutraceuticals that support healthier, happier lives for everyone, everywhere.
A drug hunter, an activist, and the mother of a child with a rare disease walk into a room. It might sound like the beginning of a joke, but trust us, the punchline is no laughing matter.
Sonya Pelia was in the room after spending 30+ years as a grassroots activist and leader. A serial entrepreneur and expert in product-led growth, she also knew a thing or two about building digital revenue engines in tech. She had seen up close exactly how the game was rigged in favor of those who have everything and still want more.
Monica Pal, a tech entrepreneur and the mother of a child with a rare disease was in the room because she had skin in the game. She had experienced firsthand how innovation and investment in health care were geared toward improving the health of the stock market at the expense of the people who suffer every day.
Together, they imagined a world where the groundbreaking scientific discovery made by Sundeep and his collaborators could help people who needed it the most, regardless of where in the world they lived.
And Blue Oak Nutraceuticals, Inc; a Public Benefit Corporation, was born.
Post-doctoral fellowship Swiss Federal Institute of Technology (ETH)
Post-doctoral fellowship Cornell University
Sundeep has almost 40 years of experience and great success in small-molecule drug discovery and development in oncology, – inflammation, the central nervous system, and cardiovascular and metabolic disorders.
Founded Advantium Pharma (2005), a contract research and manufacturing company; Sphaera Pharma (2008), establishing a new and unique model for drug discovery and development; Epirium Bio (2019), a clinical-stage biopharmaceutical company; Aayam Therapeutics (2022) advancing therapeutics for patients.
15 years ago, research in mitochondrial bioenergetics piqued his interest, and he has devoted significant time and resources to this research ever since.
Francisco has published more than 130 peer-reviewed papers.
The early focus of this work related to understanding the pathophysiology of cardiac remodeling and fibrosis with an emphasis on cardiac mechanics approaches.
Later work focused on pharmacological strategies to protect the heart from ischemic injury, and most recently he has been studying the organ protective effects of (-)-epicatechin. Pre-clinical and clinical studies have examined the effects of (-)-epicatechin on cardiac ischemic injury, exercise capacity, and metabolism/bioenergetics.
Over his career, Francisco has won numerous awards and served on the editorial board of the Journal of Molecular and Cell Cardiology, a publication of The International Society of Heart Research.
Member EmeritusMexico National Research System, Level 3
With over 275 peer-reviewed publications to his credit, his areas of expertise include
He has been the editor and reviewer of research articles for numerous publications
Robert Lustig
MD, MSL
Paul Shiels
MD, FACP
Professor of Gerosciences (Molecular Biosciences),
University of Glasgow, Scotland
Take the first step
to living a healthful life
Join us to get early updates and
exclusive discounts
